What is Relmada Therapeutics?
Relmada Therapeutics operates as a specialized biotechnology firm dedicated to the advancement of novel therapies for central nervous system (CNS) conditions. The company's primary focus is the development of REL-1017, a proprietary NMDA receptor (NMDAR) channel blocker designed to treat major depressive disorder (MDD). Unlike traditional treatments, REL-1017 is engineered to selectively target hyperactive channels, preserving essential glutamatergic neurotransmission. Beyond its flagship MDD program, the firm is actively exploring clinical-stage applications for psilocybin-based derivatives to combat neurodegenerative diseases. This dual-track approach highlights Relmada's commitment to pioneering chemical entities that offer superior efficacy and safety profiles for patients suffering from debilitating neurological and psychiatric ailments.
How much funding has Relmada Therapeutics raised?
Relmada Therapeutics has raised a total of $166.9M across 2 funding rounds:
Debt
$6.9M
Stock/Share Issuance
$160M
Debt (2017): $6.9M, investors not publicly disclosed
Stock/Share Issuance (2026): $160M, investors not publicly disclosed
Key Investors in Relmada Therapeutics
Undisclosed Institutional Investor
A private equity or institutional entity providing strategic capital to support late-stage clinical development in the biotechnology sector.
Undisclosed Venture Partner
A specialized investment firm focused on high-growth pharmaceutical companies developing novel CNS therapeutics.
Undisclosed Strategic Backer
An investment group with a mandate to support clinical-stage companies through major strategic financing rounds.
What's next for Relmada Therapeutics?
With the recent influx of capital, Relmada Therapeutics is poised to advance its late-stage development programs, with a primary focus on the regulatory milestones for REL-1017. The strategic roadmap involves scaling clinical operations and preparing for potential commercial entry, which remains a critical inflection point for the organization. Furthermore, the company is expected to deepen its investment in its neurodegenerative pipeline, utilizing its expertise in NMDAR modulation to explore new therapeutic avenues. As the firm navigates the complexities of late-stage clinical trials, the focus will remain on data integrity and the successful execution of its regulatory strategy, ensuring that its innovative chemical entities reach the market to address the significant burden of CNS-related diseases.
See full Relmada Therapeutics company page
